FIGURE 1.
Study Design. Healthy male subjects received a single oral dose of 240‐mg napabucasin containing approximately 100 μCi of 14C‐napabucasin in a phase 1, open‐label study (NCT03525405). PK, pharmacokinetic
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.